Skip to main content
Premium Trial:

Request an Annual Quote

Atugen and Asinex Pen Drug Discovery Alliance

NEW YORK, Feb. 7 (GenomeWeb News) - Atugen and Asinex have signed a cancer drug discovery and development collaboration, the companies said today.


The two partners aim to develop compounds directed against PKN3, a kinase target involved in prostate cancer. Atugen, based in Berlin, focuses on siRNA-based drugs and will contribute its target discovery and in vivo screening expertise. Asinex, located in Moscow, will provide its drug design, medicinal chemistry, and in vitro screening knowledge.


The companies said they will share the risk of the research and split future revenues equally.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.